P
ProHub
English 简体中文 繁體中文
Medium Financial Analysis Merger & Acquisition Strategic Decision Making

Goodbye Horses

#Healthcare #Biopharmaceuticals
ProHub Comment

This is a multi-stage case requiring candidates to first identify capital-raising options (particularly divestiture of non-core assets), then optimize capital allocation across investment opportunities using a profitability index approach. The case tests strategic thinking, financial analysis, and risk consideration in a healthcare M&A context.

Estimated Time 26 minutes
Difficulty Medium
Source Duke
10 / 100
Your client is the CFO of Aperture Laboratories, a leading US biopharmaceutical company with a market cap >$150B. Aperture develops and manufactures a diversified range of products and in particular prides itself on saving millions of human lives every year. The company is under investor pressure because of its slow firm value growth over the next 10 years. Investors are very anxious to see significant changes announced at the firm in the next quarter. The CFO has already identified and evaluated a number of high-growth, promising, but capital-intensive projects, and she does not have enough cash to invest in any of the opportunities — what dose she need to do next?

Clarifying Information

  1. Unknown to the CFO until now, the business development team has retained JP Morgan to assess the sale-ability of the Animal Health business. They have identified that Aperture will likely receive a 3.5x enterprise value to sales multiple for the animal health business.
  2. The animal health business has $4.2B in sales.
  3. The deal has been structured by JP Morgan to be tax-free.
Mock Interview
Interviewer

Your client is the CFO of Aperture Laboratories, a leading US biopharmaceutical company with a market cap >$150B. Aperture develops and manufactures a diversified range of products and in particular prides itself on saving millions of human lives every year. The company is under investor pressure because of its slow firm value growth over the next 10 years. Investors are very anxious to see significant changes announced at the firm in the next quarter. The CFO has already identified and evaluated a number of high-growth, promising, but capital-intensive projects, and she does not have enough cash to invest in any of the opportunities — what dose she need to do next?

You

Thanks. Before analyzing, I'd like to clarify a few key questions...

Interviewer

Good question. Let me provide some background information...

You

Based on this, I suggest analyzing from these dimensions...

AI Score
Structure Analysis Communication Business Sense Quantitative
Practicing...
Score coming soon
Practice this case with AI Mock Interview

The CFO of a large biopharmaceutical company faces investor pressure to drive growth but lacks capital for promising projects. The solution involves divesting the low-growth Animal Health division for $14.7B and strategically investing in high-NPV projects while managing execution risks.

Key Insights:

  1. Divestiture of non-core, low-growth assets can unlock significant capital for strategic initiatives while refocusing the company on its core mission
  2. Profitability index (NPV/Capital) is the optimal metric to rank projects under capital constraints, yielding highest total value creation
  3. Successful capital redeployment requires addressing multiple execution risks including buyer identification, deal timing, and project execution risk mitigation